BioInvent: Outlicensed program to Takeda moving into phase 3
During trading hours yesterday, BioInvent announced that following Takeda's initiation of the phase 3 clinical trial of mezagitamab (TAK-079) in ITP, an anti-CD38 licensed from BioInvent's R&D engine, the company received a USD1m milestone payment. Of note, Takeda is forecasting between USD1-3b
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.